Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Morphometric characteristics in pulmonary muscular arteries by study group

From: Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD

  COPD (N = 12) NOS (N = 8) NS (N = 12) p-value
N° of arteries measured by patient 10 ± 4 12 ± 6 8 ± 6 0.203
Artery diameter, μm 306 ± 65 349.33 ± 57.7 333.51 ± 18.8 0.186
Lumen area, % total area 27.7 ± 7.1 35.1 ± 8.2 36.2 ± 9.8 0.046
Intimal area, % total area 37.3 ± 7 29.4 ± 7.1 26.6 ± 11.5 0.018
Muscular area, % total area 35 ± 4.2 35.5 ± 5.9 37.2 ± 11.2 0.782
Index of narrowinga 0.299 ± 0.032 0.301 ± 0.024 0.307 ± 0.269 0.831
  1. COPD Chronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers
  2. Data are presented as median ± standard deviation. P-values are for the overall comparison by ANOVA
  3. aIndex of narrowing was estimated as the ration between the measured total area and the area extrapolated from the theoretical distended diameter: (theoretical diameter = length of the external elastic lamina/pi (π))